# Patrik Brundin

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 163 papers | 21,639 citations | 77 h-index | 147 g-index |
| 177 ext. papers | 25,085 ext. citations | 10.4 avg, IF | 7.05 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 163 | Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease.. *Neurobiology of Disease*, **2022**, 166, 105654 | 7.5 | 3 |
| 162 | Methylated Cytochrome P450 and the Solute Carrier Family of Genes Correlate With Perturbations in Bile Acid Metabolism in Parkinson's Disease.. *Frontiers in Neuroscience*, **2022**, 16, 804261 | 5.1 | 0 |
| 161 | The roles of connectivity and neuronal phenotype in determining the pattern of α-synuclein pathology in Parkinson's disease.. *Neurobiology of Disease*, **2022**, 168, 105687 | 7.5 | 1 |
| 160 | Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson's disease.. *Npj Regenerative Medicine*, **2022**, 7, 24 | 15.8 | 3 |
| 159 | Maternal Herpesviridae infection during pregnancy alters midbrain dopaminergic signatures in adult offspring.. *Neurobiology of Disease*, **2022**, 105720 | 7.5 | 0 |
| 158 | Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson's disease.. *Trends in Endocrinology and Metabolism*, **2021**, | 8.8 | 3 |
| 157 | Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson's disease models. *JCI Insight*, **2021**, 6, | 9.9 | 2 |
| 156 | Drug Repurposing for Parkinson's Disease: The International Linked Clinical Trials experience. *Frontiers in Neuroscience*, **2021**, 15, 653377 | 5.1 | 4 |
| 155 | Decreased Risk of Parkinson's Disease After Rheumatoid Arthritis Diagnosis: A Nested Case-Control Study with Matched Cases and Controls. *Journal of Parkinson's Disease*, **2021**, 11, 821-832 | 5.3 | 3 |
| 154 | Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease. *Movement Disorders*, **2021**, 36, 1772-1780 | 7 | 8 |
| 153 | An extended release GLP-1 analogue increases α-synuclein accumulation in a mouse model of prodromal Parkinson's disease. *Experimental Neurology*, **2021**, 341, 113693 | 5.7 | 2 |
| 152 | Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson's Disease. *Metabolites*, **2021**, 11, | 5.6 | 23 |
| 151 | Heterozygous GBA D409V and ATP13a2 mutations do not exacerbate pathological α-synuclein spread in the prodromal preformed fibrils model in young mice. *Neurobiology of Disease*, **2021**, 159, 105513 | 7.5 | 1 |
| 150 | Mitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function in vivo. *Stem Cells Translational Medicine*, **2021**, 10, 278-290 | 6.9 | 7 |
| 149 | Low plasma serotonin linked to higher nigral iron in Parkinson's disease.. *Scientific Reports*, **2021**, 11, 24384 | 4.9 | 0 |
| 148 | Deficits in olfactory sensitivity in a mouse model of Parkinson's disease revealed by plethysmography of odor-evoked sniffing. *Scientific Reports*, **2020**, 10, 9242 | 4.9 | 10 |
| 147 | Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. *Neurology*, **2020**, 94, 481-494 | 6.5 | 60 |

| | | | |
|---|---|---|---|
| 146 | Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. *Movement Disorders Clinical Practice*, **2020**, 7, 357-360 | 2.2 | 24 |
| 145 | Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. *Movement Disorders*, **2020**, 35, 711-715 | 7 | 104 |
| 144 | Novel approaches to counter protein aggregation pathology in Parkinson's disease. *Progress in Brain Research*, **2020**, 252, 451-492 | 2.9 | 4 |
| 143 | Alterations in odor hedonics in the 5XFAD Alzheimer's disease mouse model and the influence of sex. *Behavioral Neuroscience*, **2020**, 134, 407-416 | 2.1 | |
| 142 | Alterations in odor hedonics in the 5XFAD Alzheimer□ disease mouse model and the influence of sex.. *Behavioral Neuroscience*, **2020**, 134, 407-416 | 2.1 | 1 |
| 141 | Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. *Clinics in Geriatric Medicine*, **2020**, 36, 1-12 | 3.8 | 143 |
| 140 | Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal. *Translational Neurodegeneration*, **2020**, 9, 39 | 10.3 | 7 |
| 139 | Is COVID-19 a Perfect Storm for Parkinson's Disease?. *Trends in Neurosciences*, **2020**, 43, 931-933 | 13.3 | 58 |
| 138 | Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease. *Movement Disorders*, **2020**, 35, 2028-2037 | 7 | 25 |
| 137 | Perturbation of in vivo Neural Activity Following □Synuclein Seeding in the Olfactory Bulb. *Journal of Parkinsons Disease*, **2020**, 10, 1411-1427 | 5.3 | 5 |
| 136 | Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation. *Neurobiology of Disease*, **2020**, 134, 104623 | 7.5 | 38 |
| 135 | Lots of Movement in Gut and Parkinson's Research. *Trends in Endocrinology and Metabolism*, **2019**, 30, 687-689 | 8.8 | 2 |
| 134 | Loss of One Engrailed1 Allele Enhances Induced □Synucleinopathy. *Journal of Parkinsons Disease*, **2019**, 9, 315-326 | 5.3 | 6 |
| 133 | Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. *Neurology*, **2019**, 92, 329-337 | 6.5 | 144 |
| 132 | Microglia affect □synuclein cell-to-cell transfer in a mouse model of Parkinson's disease. *Molecular Neurodegeneration*, **2019**, 14, 34 | 19 | 71 |
| 131 | Can infections trigger alpha-synucleinopathies?. *Progress in Molecular Biology and Translational Science*, **2019**, 168, 299-322 | 4 | 35 |
| 130 | Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let's talk about the lipids in the room. *Npj Parkinsons Disease*, **2019**, 5, 23 | 9.7 | 23 |
| 129 | □Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb. *Acta Neuropathologica Communications*, **2019**, 7, 221 | 7.3 | 41 |

| | | | |
|---|---|---|---|
| 128 | Genetically engineered stem cell-derived neurons can be rendered resistant to alpha-synuclein aggregate pathology. *European Journal of Neuroscience*, **2019**, 49, 316-319 | 3.5 | 2 |
| 127 | Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis. *Trends in Neurosciences*, **2019**, 42, 4-13 | 13.3 | 138 |
| 126 | A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. *Journal of Parkinson's Disease*, **2019**, 9, 31-61 | 5.3 | 33 |
| 125 | The Linked Clinical Trials initiative (LCT) for Parkinson's disease. *European Journal of Neuroscience*, **2019**, 49, 307-315 | 3.5 | 12 |
| 124 | The concept of alpha-synuclein as a prion-like protein: ten years after. *Cell and Tissue Research*, **2018**, 373, 161-173 | 4.2 | 85 |
| 123 | Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic. *Movement Disorders*, **2018**, 33, 684-696 | 7 | 101 |
| 122 | The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. *Neurobiology of Disease*, **2018**, 109, 226-248 | 7.5 | 136 |
| 121 | Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration. *Molecular Neurodegeneration*, **2018**, 13, 28 | 19 | 34 |
| 120 | Fire prevention in the Parkinson's disease brain. *Nature Medicine*, **2018**, 24, 900-902 | 50.5 | 3 |
| 119 | Prion-like propagation of pathology in Parkinson disease. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2018**, 153, 321-335 | 3 | 42 |
| 118 | Prion-Like Propagation in Neurodegenerative Diseases **2018**, 189-242 | | |
| 117 | Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. *Neurology*, **2018**, 90, 74-82 | 6.5 | 10 |
| 116 | Spread of aggregates after olfactory bulb injection of synuclein fibrils is associated with early neuronal loss and is reduced long term. *Acta Neuropathologica*, **2018**, 135, 65-83 | 14.3 | 98 |
| 115 | Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson's Disease. *Metabolites*, **2018**, 8, | 5.6 | 22 |
| 114 | The vermiform appendix impacts the risk of developing Parkinson's disease. *Science Translational Medicine*, **2018**, 10, | 17.5 | 135 |
| 113 | New Frontiers in Parkinson's Disease: From Genetics to the Clinic. *Journal of Neuroscience*, **2018**, 38, 9375-9382 | 6.0 | 24 |
| 112 | Cancer enzyme affects Parkinson's disease. *Science*, **2018**, 362, 521-522 | 33.3 | 8 |
| 111 | Biochemical Profiling of the Brain and Blood Metabolome in a Mouse Model of Prodromal Parkinson's Disease Reveals Distinct Metabolic Profiles. *Journal of Proteome Research*, **2018**, 17, 2460-2469 | 5.6 | 32 |

| | | | |
|---|---|---|---|
| 110 | Precision medicine for disease modification in Parkinson disease. *Nature Reviews Neurology*, **2017**, 13, 119-126 | 15 | 103 |
| 109 | Solving the conundrum of insoluble protein aggregates. *Lancet Neurology, The*, **2017**, 16, 258-259 | 24.1 | 7 |
| 108 | Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. *Movement Disorders*, **2017**, 32, 319-324 | 7 | 111 |
| 107 | Parkinson disease. *Nature Reviews Disease Primers*, **2017**, 3, 17013 | 51.1 | 1700 |
| 106 | Therapeutic approaches to target alpha-synuclein pathology. *Experimental Neurology*, **2017**, 298, 225-235 | 5.7 | 133 |
| 105 | Prying into the Prion Hypothesis for Parkinson's Disease. *Journal of Neuroscience*, **2017**, 37, 9808-9818 | 6.6 | 153 |
| 104 | Novel animal model defines genetic contributions for neuron-to-neuron transfer of α-synuclein. *Scientific Reports*, **2017**, 7, 7506 | 4.9 | 27 |
| 103 | Is Exenatide a Treatment for Parkinson's Disease?. *Journal of Parkinson's Disease*, **2017**, 7, 451-458 | 5.3 | 22 |
| 102 | Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson's Disease?. *Journal of Parkinson's Disease*, **2017**, 7, 577-587 | 5.3 | 15 |
| 101 | Mechanisms for cell-to-cell propagation no longer lag behind. *Movement Disorders*, **2016**, 31, 1798-1799 | 7 | 2 |
| 100 | Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?. *Journal of Parkinson's Disease*, **2016**, 6, 57-63 | 5.3 | 47 |
| 99 | Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson's disease etiology. *Scientific Reports*, **2016**, 6, 30509 | 4.9 | 42 |
| 98 | Nilotinib - Differentiating the Hope from the Hype. *Journal of Parkinson's Disease*, **2016**, 6, 519-22 | 5.3 | 27 |
| 97 | Alpha-synuclein propagation: New insights from animal models. *Movement Disorders*, **2016**, 31, 161-8 | 7 | 79 |
| 96 | Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. *Science Translational Medicine*, **2016**, 8, 368ra174 | 17.5 | 99 |
| 95 | How strong is the evidence that Parkinson's disease is a prion disorder?. *Current Opinion in Neurology*, **2016**, 29, 459-66 | 7.1 | 48 |
| 94 | Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 6544-9 | 11.5 | 182 |
| 93 | Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. *Journal of Experimental Medicine*, **2016**, 213, 1759-78 | 16.6 | 232 |

| | | | |
|---|---|---|---|
| 92 | Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. *Journal of Neurochemistry*, **2016**, 139 Suppl 1, 275-289 | 6 | 53 |
| 91 | Parkinson disease: Laying the foundations for disease-modifying therapies in PD. *Nature Reviews Neurology*, **2015**, 11, 553-5 | 15 | 10 |
| 90 | A cell culture model for monitoring β-synuclein cell-to-cell transfer. *Neurobiology of Disease*, **2015**, 77, 266-75 | 7.5 | 60 |
| 89 | Spreading of β-synuclein in the face of axonal transport deficits in Parkinson's disease: a speculative synthesis. *Neurobiology of Disease*, **2015**, 77, 276-83 | 7.5 | 43 |
| 88 | Basic science breaks through: New therapeutic advances in Parkinson's disease. *Movement Disorders*, **2015**, 30, 1521-7 | 7 | 16 |
| 87 | Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation. *Journal of Parkinson's Disease*, **2015**, 5, 413-24 | 5.3 | 55 |
| 86 | Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. *Neurobiology of Disease*, **2015**, 73, 70-82 | 7.5 | 59 |
| 85 | Acceleration of β-synuclein aggregation by exosomes. *Journal of Biological Chemistry*, **2015**, 290, 2969-82 | 5.4 | 228 |
| 84 | Alpha-synuclein transfers from neurons to oligodendrocytes. *Glia*, **2014**, 62, 387-98 | 9 | 170 |
| 83 | Is exenatide the next big thing in Parkinson's disease?. *Journal of Parkinson's Disease*, **2014**, 4, 345-7 | 5.3 | 4 |
| 82 | Gut feelings about smoking and coffee in Parkinson's disease. *Movement Disorders*, **2014**, 29, 976-9 | 7 | 72 |
| 81 | The role of Galectin-3 in β-synuclein-induced microglial activation. *Acta Neuropathologica Communications*, **2014**, 2, 156 | 7.3 | 48 |
| 80 | Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. *JAMA Neurology*, **2014**, 71, 83-7 | 17.2 | 205 |
| 79 | Transfer of human β-synuclein from the olfactory bulb to interconnected brain regions in mice. *Acta Neuropathologica*, **2013**, 126, 555-73 | 14.3 | 181 |
| 78 | Inflammation and β-synuclein's prion-like behavior in Parkinson's disease--is there a link?. *Molecular Neurobiology*, **2013**, 47, 561-74 | 6.2 | 148 |
| 77 | β-synuclein: the long distance runner. *Brain Pathology*, **2013**, 23, 350-7 | 6 | 93 |
| 76 | Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?. *Movement Disorders*, **2013**, 28, 31-40 | 7 | 249 |
| 75 | Adsorption of β-synuclein to supported lipid bilayers: positioning and role of electrostatics. *ACS Chemical Neuroscience*, **2013**, 4, 1339-51 | 5.7 | 65 |

| | | | |
|---|---|---|---|
| 74 | What's to like about the prion-like hypothesis for the spreading of aggregated Synuclein in Parkinson disease?. *Prion*, **2013**, 7, 92-7 | 2.3 | 53 |
| 73 | NGF rescues hippocampal cholinergic neuronal markers, restores neurogenesis, and improves the spatial working memory in a mouse model of Huntington's Disease. *Journal of Huntingtons Disease*, **2013**, 2, 69-82 | 1.9 | 26 |
| 72 | Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. *Journal of Parkinsons Disease*, **2013**, 3, 231-9 | 5.3 | 32 |
| 71 | Neuropathology in transplants in Parkinson's disease: implications for disease pathogenesis and the future of cell therapy. *Progress in Brain Research*, **2012**, 200, 221-41 | 2.9 | 39 |
| 70 | Can Parkinson's disease pathology be propagated from one neuron to another?. *Progress in Neurobiology*, **2012**, 97, 205-19 | 10.9 | 83 |
| 69 | Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. *Stem Cells*, **2012**, 30, 2054-62 | 5.8 | 136 |
| 68 | The adult human brain harbors multipotent perivascular mesenchymal stem cells. *PLoS ONE*, **2012**, 7, e35577 | 3.7 | 159 |
| 67 | Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. *PLoS ONE* , **2012**, 7, e39465 | 3.7 | 186 |
| 66 | Journal of Parkinson's disease. *Journal of Parkinsons Disease*, **2011**, 1, 1 | 5.3 | |
| 65 | Signs of degeneration in 12-22-year old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease. *Journal of Parkinsons Disease*, **2011**, 1, 83-92 | 5.3 | 79 |
| 64 | Membrane interaction of Synuclein in different aggregation states. *Journal of Parkinsons Disease*, **2011**, 1, 359-71 | 5.3 | 81 |
| 63 | Caspase signalling controls microglia activation and neurotoxicity. *Nature*, **2011**, 472, 319-24 | 50.4 | 406 |
| 62 | Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. *Journal of Clinical Investigation*, **2011**, 121, 715-25 | 15.9 | 616 |
| 61 | Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. *Human Molecular Genetics*, **2011**, 20, 2225-37 | 5.6 | 144 |
| 60 | Prion-like transmission of protein aggregates in neurodegenerative diseases. *Nature Reviews Molecular Cell Biology*, **2010**, 11, 301-7 | 48.7 | 549 |
| 59 | Neural grafting in Parkinson's disease Problems and possibilities. *Progress in Brain Research*, **2010**, 184, 265-94 | 2.9 | 97 |
| 58 | Are synucleinopathies prion-like disorders?. *Lancet Neurology, The*, **2010**, 9, 1128-38 | 24.1 | 191 |
| 57 | Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. *Movement Disorders*, **2010**, 25, 1091-6 | 7 | 157 |

| | | | |
|---|---|---|---|
| 56 | Neurogenin2 directs granule neuroblast production and amplification while NeuroD1 specifies neuronal fate during hippocampal neurogenesis. *PLoS ONE*, **2009**, 4, e4779 | 3.7 | 113 |
| 55 | Lewy body pathology in long-term fetal nigral transplants: is Parkinson's disease transmitted from one neural system to another?. *Neuropsychopharmacology*, **2009**, 34, 254 | 8.7 | 34 |
| 54 | Beyond the brain: widespread pathology in Huntington's disease. *Lancet Neurology, The*, **2009**, 8, 765-74 | 24.1 | 257 |
| 53 | Research in motion: the enigma of Parkinson's disease pathology spread. *Nature Reviews Neuroscience*, **2008**, 9, 741-5 | 13.5 | 251 |
| 52 | Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. *Nature Medicine*, **2008**, 14, 501-3 | 50.5 | 1293 |
| 51 | Increased metabolism in the R6/2 mouse model of Huntington's disease. *Neurobiology of Disease*, **2008**, 29, 41-51 | 7.5 | 105 |
| 50 | Critical issues of clinical human embryonic stem cell therapy for brain repair. *Trends in Neurosciences*, **2008**, 31, 146-53 | 13.3 | 157 |
| 49 | A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. *Journal of Experimental Medicine*, **2008**, 205, 1869-77 | 16.6 | 437 |
| 48 | Future Cell- and Gene-Based Therapies for Parkinson's Disease **2008**, 145-156 | | |
| 47 | Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. *Human Molecular Genetics*, **2006**, 15, 1713-21 | 5.6 | 110 |
| 46 | Important Aspects of Surgical Methodology for Transplantation in Parkinson's Disease **2006**, 131-165 | | 5 |
| 45 | Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice. *Neurobiology of Disease*, **2005**, 20, 744-51 | 7.5 | 148 |
| 44 | Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. *Behavioural Brain Research*, **2005**, 162, 1-10 | 3.4 | 245 |
| 43 | The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. *NeuroRx*, **2005**, 2, 447-64 | | 151 |
| 42 | The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. *Human Molecular Genetics*, **2005**, 14, 565-74 | 5.6 | 116 |
| 41 | Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. *Journal of Neuroscience*, **2005**, 25, 6329-42 | 6.6 | 184 |
| 40 | Orexin loss in Huntington's disease. *Human Molecular Genetics*, **2005**, 14, 39-47 | 5.6 | 222 |
| 39 | No evidence for new dopaminergic neurons in the adult mammalian substantia nigra. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 10177-82 | 11.5 | 213 |

| | | | |
|---|---|---|---|
| 38 | Neural transplantation for the treatment of Parkinson's disease. *Lancet Neurology, The*, **2003**, 2, 437-45 | 24.1 | 278 |
| 37 | Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. *Brain Research*, **2003**, 970, 47-57 | 3.7 | 106 |
| 36 | The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. *Neuron*, **2003**, 40, 427-46 | 13.9 | 790 |
| 35 | Dyskinesias following neural transplantation in Parkinson's disease. *Nature Neuroscience*, **2002**, 5, 627-8 | 25.5 | 365 |
| 34 | Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. *Nature Reviews Neuroscience*, **2002**, 3, 932-42 | 13.5 | 901 |
| 33 | Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. *Human Molecular Genetics*, **2002**, 11, 2395-407 | 5.6 | 191 |
| 32 | Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. *Neuron*, **2002**, 33, 849-60 | 13.9 | 506 |
| 31 | Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. *Journal of Biological Chemistry*, **2002**, 277, 38884-94 | 5.4 | 260 |
| 30 | Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. *Journal of Neurochemistry*, **2001**, 78, 694-703 | 6 | 45 |
| 29 | Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. *European Journal of Neuroscience*, **2001**, 14, 1425-35 | 3.5 | 34 |
| 28 | Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. *European Journal of Neuroscience*, **2001**, 14, 1492-504 | 3.5 | 117 |
| 27 | Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. *Journal of Neuropathology and Experimental Neurology*, **2001**, 60, 741-52 | 3.1 | 161 |
| 26 | Improving the survival of grafted dopaminergic neurons: a review over current approaches. *Cell Transplantation*, **2000**, 9, 179-95 | 4 | 287 |
| 25 | Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. *Annals of Neurology*, **2000**, 48, 689-695 | 9.4 | 211 |
| 24 | Differential effects of Bcl-2 overexpression on fibre outgrowth and survival of embryonic dopaminergic neurons in intracerebral transplants. *European Journal of Neuroscience*, **1999**, 11, 3073-81 | 3.5 | 34 |
| 23 | Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. *Nature Neuroscience*, **1999**, 2, 1137-40 | 25.5 | 582 |
| 22 | Caspase inhibition reduces apoptosis and increases survival of nigral transplants. *Nature Medicine*, **1999**, 5, 97-100 | 50.5 | 258 |
| 21 | CuZn superoxide dismutase transgenic retinal transplants. *Graefes Archive for Clinical and Experimental Ophthalmology*, **1999**, 237, 336-41 | 3.8 | 7 |

| | | | |
|---|---|---|---|
| 20 | Survival of expanded dopaminergic precursors is critical for clinical trials. *Nature Neuroscience*, **1998**, 1, 537 | 25.5 | 36 |
| 19 | Quinolinic acid-induced inflammation in the striatum does not impair the survival of neural allografts in the rat. *European Journal of Neuroscience*, **1998**, 10, 2595-606 | 3.5 | 35 |
| 18 | Addition of Lateral Ganglionic Eminence to Rat Mesencephalic Grafts Affects Fiber Outgrowth but Does not Enhance Function. *Cell Transplantation*, **1997**, 6, 277-286 | 4 | 17 |
| 17 | Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. *Annals of Neurology*, **1997**, 42, 95-107 | 9.4 | 276 |
| 16 | Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. *Nature Medicine*, **1995**, 1, 226-31 | 50.5 | 136 |
| 15 | Sequential intracerebral transplantation of allogeneic and syngeneic fetal dopamine-rich neuronal tissue in adult rats: will the first graft be rejected?. *Cell Transplantation*, **1993**, 2, 307-17 | 4 | 69 |
| 14 | Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). *New England Journal of Medicine*, **1992**, 327, 1556-63 | 59.2 | 494 |
| 13 | Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. *Annals of Neurology*, **1992**, 31, 155-65 | 9.4 | 323 |
| 12 | Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. *Annals of Neurology*, **1992**, 31, 166-73 | 9.4 | 279 |
| 11 | Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts. *Restorative Neurology and Neuroscience*, **1991**, 2, 123-35 | 2.8 | 76 |
| 10 | Reformation of long axon pathways in adult rat central nervous system by human forebrain neuroblasts. *Nature*, **1990**, 347, 556-8 | 50.4 | 237 |
| 9 | In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervated rat striatum. *Neuron*, **1990**, 5, 393-402 | 13.9 | 214 |
| 8 | Survival, growth and function of dopaminergic neurons grafted to the brain. *Progress in Brain Research*, **1987**, 71, 293-308 | 2.9 | 85 |
| 7 | Mechanisms of action of intracerebral neural implants: studies on nigral and striatal grafts to the lesioned striatum. *Trends in Neurosciences*, **1987**, 10, 509-516 | 13.3 | 290 |
| 6 | Monitoring of cell viability in suspensions of embryonic CNS tissue and its use as a criterion for intracerebral graft survival. *Brain Research*, **1985**, 331, 251-9 | 3.7 | 257 |
| 5 | T cells limit accumulation of aggregate pathology following intrastriatal injection of □synuclein fibrils | | 1 |
| 4 | Prion-like transmission of protein aggregates in neurodegenerative diseases | | 1 |
| 3 | Alpha-synuclein supports interferon stimulated gene expression in neurons | | 3 |

# List of Publications

| | | |
|---|---|---|
| 2 | Nilotinib in Patients with Advanced Parkinson's Disease: A Randomized Phase 2A Study (NILO-PD) | 6 |
| 1 | Experimental colitis drives enteric alpha-synuclein accumulation and Parkinson-like brain pathology | 3 |